Profile data is unavailable for this security.
About the company
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
- Revenue in CAD (TTM)2.01m
- Net income in CAD-25.08m
- Incorporated2005
- Employees29.00
- LocationSpectral Medical Inc135 The West Mall, Unit 2TORONTO M9C 1C2CanadaCAN
- Phone+1 (416) 626-3233
- Fax+1 (416) 626-3233
- Websitehttps://spectraldx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CellSeed Inc | 1.80m | -8.62m | 147.59m | 35.00 | -- | 7.47 | -- | 82.18 | -30.72 | -30.72 | 6.40 | 63.29 | 0.0892 | 1.65 | 7.91 | 5,699,172.00 | -42.79 | -49.69 | -46.02 | -54.55 | 55.38 | 63.66 | -479.79 | -428.62 | 16.42 | -5,460.76 | 0.0651 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Spectral Medical Inc | 2.01m | -25.08m | 152.72m | 29.00 | -- | -- | -- | 76.13 | -0.0895 | -0.0896 | 0.0072 | -0.1106 | 0.2369 | 3.88 | 3.80 | 69,172.41 | -296.18 | -109.65 | -- | -175.35 | 39.78 | 63.74 | -1,250.20 | -445.72 | 0.2057 | -1.22 | -- | -- | -4.14 | -16.08 | -104.12 | -- | 31.53 | -- |
| Dali Pharmaceutical Co Ltd | 11.94m | -4.72m | 152.79m | 272.00 | -- | 2.18 | -- | 12.79 | -0.111 | -0.111 | 0.2806 | 1.64 | 0.1347 | 1.15 | 10.58 | 226,632.80 | -5.33 | -2.31 | -6.29 | -2.77 | 2.77 | 65.39 | -39.55 | -7.00 | 2.81 | -- | 0.052 | -- | -34.06 | -26.30 | -13.16 | -- | 16.34 | -- |
| Darya-Varia Laboratoria Tbk PT | 189.35m | 17.21m | 166.95m | 1.27k | 9.72 | 1.27 | 7.36 | 0.8817 | 172.87 | 172.87 | 1,903.34 | 1,318.69 | 1.00 | 2.10 | 3.58 | 1,681,663,000.00 | 9.11 | 8.45 | 12.10 | 11.41 | 52.71 | 52.21 | 9.09 | 8.83 | 1.95 | -- | 0.0008 | 75.64 | -1.36 | 2.16 | -2.03 | -6.12 | 16.57 | 0.1862 |
